The online version of this article, along with updated information and services, is
In-stent restenosis (ISR) is a novel pathobiologic process, histologically distinct from restenosis after balloon angioplasty and comprised largely of neointima formation. As percutaneous coronary intervention increasingly involves the use of stents, ISR is also becoming correspondingly more frequent. In this review, we examine the available studies of the histology and pathogenesis of ISR, with particular reference to porcine and other animal models. An overview of mechanical treatments is then provided, which includes PTCA, directional coronary atherectomy and high speed rotational atherectomy. Radiation-based therapies are discussed, including a summary of current problems associated with this modality of treatment. Finally, novel strategies for the prevention of ISR are addressed, including novel developments in stents and stent coatings, conventional drugs, nucleic acid-based drugs and gene transfer. Until recently, limited pharmacologic and mechanical treatment options have been available for both treatment and prevention of ISR. However, recent advances in gene modification and gene transfer therapies and, more particularly, in local stent-based drug delivery systems make it conceivable that the incidence of ISR will now be seriously challenged. Restenosis, defined as "the arterial healing response after injury incurred during transluminal coronary revascularization" (1) has been the principal drawback of coronary angioplasty since its inception nearly 25 years ago. The only widely accepted means of reducing restenosis has been the coronary stent, and the last five years have seen a prompt and widespread adoption of coronary stents, following the demonstration of reduced restenosis rates compared with percutaneous transluminal coronary angioplasty (PTCA) alone for comparable lesions (2) (3) (4) . Coronary revascularization now generally involves the use of a stent in more than 70% of cases (5) . Coincident with this increased stent use has been the more widespread treatment of more complex lesions and the realization that in-stent restenosis (ISR) occurs in 10% to 50% of cases currently treated in everyday practice and estimated to have occurred in 150,000 patients in 1999 in the U.S. alone (6 -9) . Therefore, the problem of ISR is becoming at least as important as restenosis after PTCA.
In-stent restenosis has been classified on the basis of length of restenosis in relation to stented length (10) . Four types of ISR have been defined: I) focal (Յ10 mm length); II) diffuse (ISR Ͼ10 mm within the stent); III) proliferative (ISR Ͼ10 mm extending outside the stent); and IV) occlusive ISR. Type I has been further subdivided into types IA to ID based on the site of focal ISR in relation to the stent (10) . An additional type of ISR has been proposed, that of "aggressive ISR," defined as ISR that is longer and/or more severe than the original lesion (9) . This type is noteworthy in that the clinical course is not benign, with patients more likely to have more severe symptoms and higher rates of myocardial infarction (9) .
Histologically, ISR is quite distinct from restenosis after balloon angioplasty (1, 11, 12) . Postangioplasty restenosis is thought to involve vessel elastic recoil, negative remodelling or contraction, thrombus at the site of injury, smooth muscle cell (SMC) proliferation and migration and excessive extracellular matrix production. These last two processes contribute to neointima (NI) formation (1, 13) . In contrast, intravascular ultrasound studies suggest that stenting virtually eliminates vessel elastic recoil and negative remodelling and that ISR is largely a result of NI formation alone (12, 14, 15) . Neointima is composed principally of proliferating SMC (16, 17) and extracellular matrix (18) . Peristent thrombus has not been thought to play an important role in NI formation-at least in the pig model of stenting (19)-although recent observations suggest it may have some influence, particularly in the setting of hyperglycemia (20 -22) .
A number of variables are known to increase the risk of ISR. Patients with diabetes or a history of prior restenosis have a higher rate of ISR (23, 24) . There is some evidence that genetic factors play a role, examples being the PI A polymorphism of glycoprotein IIIa and a mutant form of methylenetetrahydrofolate reductase that appear to increase the risk of ISR, whereas allele 2 of the interleukin IL-1ra gene appears to be protective (25) (26) (27) (28) . Patients positive for allergic patch-test reactions to the stent components nickel and molybdenum also appear to have increased rates of ISR (29) . Procedural-related variables have also been implicated. For example, the greater the stented length, the number of stents used or lesions in vessels that are small, occluded, at vessel ostia or in vein grafts are all associated with increased ISR rates (30 -35) . The postprocedural minimal lumen diameter is also an important, well-documented predictor of subsequent ISR rates (36) . Animal models of ISR. Animal models have provided insights into the mechanisms of ISR and are widely used to evaluate candidate drug inhibitors of ISR (1, 37) . The principal model currently used is that of porcine coronary stenting (38) , although stenting of the porcine carotid and iliac arteries has been described (39, 40) , and similar models have also been proposed in the rat, rabbit and primate (41) (42) (43) . These small animal models of rat carotid and rabbit iliac stenting have the advantages of availability and low cost but are in peripheral vessels, histologically quite distinct from human coronaries, and are not widely used (37) . Large animal models of nonhuman primates have also been proposed as models of ISR, given that many species develop spontaneous atherosclerosis with lesions similar to humans (44, 45) , but animals are expensive and difficult to maintain (37) , and most studies have been reported using peripheral vessels (46, 47) .
The porcine model of ISR is currently and widely used (37) . In this model, oversized metallic stents are placed into the coronary arteries of domestic crossbred swine. A thick NI is reliably induced by 28 days (Fig. 1) . The model is attractive for a number of reasons; the response to deep injury is very similar between domestic pig and normal human coronary arteries (48) , and the adaptive response in the pig is more profound in pigs fed a hypercholesterolemic diet (49) . Moreover, since the size and anatomic distribution of porcine coronary arteries are similar to those of the human, angiography, intravascular ultrasound, instrumentation and stent deployment are all similar to the clinical situation.
The porcine model is also useful in that the degree of injury can be quantitated. The anatomic depth to which the stent strut penetrates the vessel wall has been correlated with the induced NI thickness (38) . For stents with multiple struts, an "injury score" can be derived for each strut and a mean score for the vessel as a whole (Fig. 1) . Injury score can then be correlated to the vessel cross-sectional mean NI area (38) or percent stenosis (50) . More recently, in addition to the injury score an "inflammation score" has also been described (50) . This is derived from the extent and severity of inflammatory cell infiltrate around the stent struts. A correlation exists between the inflammatory score and the Figure 1 . In-stent restenosis after porcine coronary stenting. Nonatherosclerotic porcine coronary artery 30 days after stenting with oversized balloon. Vessel excised, processed in methylmethacrylate, cut, polished and stained with haemotoxylin and eosin (originally at 2ϫ magnification). The injury score for each stent strut is shown according to the definitions: 0 ϭ internal elastic lamina (IEL) intact, endothelium denuded, media compressed but not lacerated; 1 ϭ IEL lacerated, media compressed but not lacerated; 2 ϭ IEL lacerated, media lacerated, external elastic lamina (EEL) compressed but not lacerated; 3 ϭ EEL lacerated, media contains large lacerations, stent strut may extend into the adventitia. The injury score for the vessel section is calculated as (total of individual stent strut injury scores) / (number of stent struts in section) and equals 21/10 ϭ 2.1 based on the original description (38) . L ϭ lumen; M ϭ media; N ϭ neointima; S ϭ stent strut; Th ϭ thrombus.
Abbreviations and Acronyms

ARTIST
degree of arterial injury and with NI thickness, suggesting inflammation also plays an important role in this model (50) .
There is a time-dependent progression in the cellular response to stenting in the pig model (19) . At 24 h after stenting, immediately adjacent to the stent struts, there are acute inflammatory cells and thrombus, containing platelets and fibrin (19) . At one week, this thrombus has become organized, and macrophages are evident. By two to four weeks, although some chronic inflammatory cells remain, the predominant cell type is the fully differentiated SMC (19) . Although histologic studies in the human are necessarily less detailed, a similar progression of thrombus formation, inflammatory cell and SMC infiltration has been observed from postmortem studies (22) .
Despite these similarities, the pig model, like other models, has limitations. The preinjured arteries are normal, nonatherosclerotic vessels (38) . In the pig, the stent struts induce injury directly, by medial cell compression or laceration (38) . In the human, direct medial injury occurs by only 32% of stent struts, with most struts being in contact with atheromatous plaque and not media (22) . Thus, in the human, a stent strut "injury score" is not a practical calculation, but it is noteworthy that the amount of NI formation increases with increasing stent area relative to proximal reference lumen area (22) . Another difference between the models is that in the pig the degree of ISR is examined at one month, compared with the three to six months that is the peak period of ISR development in humans (3, 51) . Despite these limitations, the porcine coronary model has gained the most widespread use of any of the large animal models (37) and continues to be used to evaluate potential new antirestenotic drugs (52), gene-based (53) and radiation-based therapies (54) .
TREATMENTS FOR ISR
In any discussion of the modalities of treatment for ISR it should be pointed out that many of these modalities can also be used in combination with stenting of de novo coronary lesions and, therefore, can also be viewed as preventing ISR. For the most part, mechanical and radiation-based therapies have been used to treat ISR, whereas drug and stent-based therapies have been used in de novo lesions to try to prevent ISR. The discussion in the subsequent text follows this pattern. Mechanical treatments. PTCA. Percutaneous transluminal coronary angioplasty-redilating within the segment of ISR-is the most commonly available treatment. The procedure is technically straightforward but usually does not achieve a lumen diameter as large as that achieved at the time of original stent deployment, even using larger balloons at high pressures (55) . It has been suggested that 56% of the achieved lumenal enlargement occurs through additional stent expansion, and 44% is due to a reduction or compression of NI tissue (55) . Intravascular ultrasound studies have suggested that this NI tissue may undergo reintrusion through stent struts soon after initial balloon expansion, leading to an acute loss of benefit (56) . In patients with ISR lesions Ͻ10 mm in length (type I or II) treated with PTCA alone, recurrence of restenosis occurs in 19% to 35%; for types III or IV, treated with PTCA in combination with other therapies, recurrence rates are 50% and 83%, respectively (10, 55) . In view of these generally poor results, therefore, attention has focused on mechanical techniques that involve removal of tissue.
DIRECTIONAL CORONARY ATHERECTOMY (DCA).
Directional coronary atherectomy is an attractive option for the treatment of ISR in that there is some evidence that pre-existing plaque burden contributes to ISR (57) so that plaque debulking before stenting using DCA has been proposed as a technique to lower ISR (58) . Directional coronary atherectomy has been demonstrated to remove NI tissue within the stent and results in an acute gain in lumen diameter (57, 59) . In a small series of 45 patients undergoing DCA for diffuse ISR, there was a low rate of target lesion revascularization at 12 months of 28.3% (60). However, concerns over increased morbidity in general after DCA (61) and specific concerns over stent strut fracture and disruption after DCA for ISR (62) have hindered broad adoption of this technique.
HIGH SPEED ROTATIONAL ATHERECTOMY (HSRA).
High speed rotational atherectomy results in the efficient removal of NI, and, if followed by PTCA, these acute outcomes can be improved additionally by further stent expansion and tissue extrusion. Initial registry data suggest this technique is feasible and safe, resulting in restenosis rates of 28% at 13-month follow-up (63) . However, results of two subsequent randomized trials have provided conflicting data. The first of these, the Randomized Trial of Rotational Atherectomy Versus Balloon Angioplasty for In-Stent Restenosis (ROSTER), was a single center trial comparing 75 patients undergoing PTCA with 75 patients undergoing HSRA and found clinical restenosis rates of 20% versus 43% (p ϭ 0.01), respectively (64) . These findings were supported by registry data suggesting improved one-year outcomes for HSRA compared with PTCA (65) and satisfactory outcomes in patients with proximal left anterior descending lesions treated with HSRA with adjunctive intravascular ultrasound (66) . However, the Angioplasty Versus Rotational Atherectomy for Treatment of In-Stent Restenosis Trial (ARTIST) demonstrated the opposite effect. For patients with diffuse ISR (10 mm to 50 mm length), 146 patients undergoing PTCA had an angiographic restenosis rate of 51.2% compared with 152 patients undergoing HRSA with a restenosis rate of 64.8% (p ϭ 0.04) (67) .
OTHER DEVICES. Given the lack of a clear benefit for any of the above techniques, a number of other devices have been tested in the treatment of ISR. These include laser angioplasty, helical atherectomy and the cutting balloon (67-70).
The cutting balloon used for treatment of ISR has been associated with improved clinical and angiographic variables at follow-up in a matched comparison with HSRA, PTCA and stenting and is currently widely used in a number of centers (70) . Additional stenting within the region of ISR has also been proposed. This is a straightforward technique generally giving an improved angiographic result compared with PTCA alone (71) . However, additional stenting may result in greater procedural creatine kinase-MB release (72) , and the longer-term results are similar to angioplasty alone (73, 74) . Radiation treatment for ISR. Radiation therapy (or brachytherapy from the Greek "brakhus" meaning short, referring to the short distance between the intravascular radiation source and target cells) (75, 76 ) is a recently proposed therapy for ISR, currently the subject of a number of clinical trials and debate (77, 78) . Intravascular radiation is thought to disrupt cellular deoxyribonucleic acid (DNA) and actively dividing intimal and medial cells (79) . This mechanism is analogous to radiation therapies used in conditions of neoplastic and non-neoplastic proliferative diseases (80) . Since a large number of the SMCs contained in ISR lesions are proliferating, as assessed by immunohistochemistry for proliferating cell nuclear antigen and other markers of proliferation (16) , this approach has been enthusiastically explored.
Radiation therapy has been tested from two main sources: ␥ and ␤ (Table 1) (81) . To date, the principal ␥ source tested has been a locally delivered 132 Iridium (Ir) wire (6, 82, 83) ; ␤ sources include a 32 Phosphorus (P) wire (84) and a 32 P-␤-emitting stent (85) . ␤-radiation derives from particulate energy in the form of electrons and, therefore, has limited penetration, with most therapeutic benefit gained within 2 mm to 3 mm of the source. In contrast, ␥-radiation is in the form of photons, penetrates well beyond the vessel wall and is not thought to be completely shielded by standard lead aprons and shields used in catheterization laboratories, although the amount of extra shielding required depends on the total ␥-radiation dose and is currently the matter of some debate (76, 78, 86) .
Most clinical experience has been with the ␥ source using a 132 Ir wire or ribbon (6, 82, 83) . The GAMMA-I trial and ␥-Washington Radiation for In-Stent Restenosis (WRIST) trials randomized 252 and 130 patients with ISR, respectively, to receive percutaneous coronary intervention with either 132 Ir wire or placebo (6, 82) . The Scripps Coronary Radiation to Inhibit Proliferation Post Stenting (SCRIPPS) trial randomized 26 patients to 132 Ir wire and 29 patients to placebo after stenting for restenosis following coronary intervention, 62% of which was ISR (83) . In all three studies, there were significantly reduced rates of angiographic ISR at six months (21.6% vs. 50.5%; 29.2% vs. 67.7%; 17% vs. 54%, respectively, all p ϭ Յ 0.01). Subsequent trials in selected subgroups have demonstrated similar effects ( Table 1 ). The benefit beyond six months, however, appears less robust. At three-year follow-up of patients in the SCRIPPS trial, a reduction in ISR for the treatment group was still evident (33.3% vs. 63.6%, p Ͻ 0.05), though the magnitude was less at three years than it was at six months (48% vs. 69%). There was a continuing loss of lumenal diameter confined to the treatment group out to three years, raising the possibility that ␥-radiation may simply delay ISR rather than reduce it (87).
To date, there is more limited experience using ␤-radiation, though there are a number of trials ongoing at the time of writing (81, 88) . ␤ sources include strontium 90 (Sr-90), 90 Yttrium (89) and a 32 P source wire (84) . In the Stents And Radiation Therapy (START) trial, 485 patients with ISR Ͻ20 mm in length were treated with angioplasty and irradiation with Sr-90/Y or placebo (81) . Angiographic restenosis at eight months was improved with radiation (29% vs. 45%, p ϭ 0.001), and there was no stent thrombosis in the treatment group (81) . 90 Yttrium has been used in a dose-finding study in 181 patients after PTCA of de novo lesions, with stenting performed in 28%. There was a significant, dose-dependent decrease in restenosis rates up to the maximum used dose of 18 Gy, without an increase in late complications (89) . This source has yet to be used for the treatment of ISR. In the Proliferation Reduction with Vascular Energy Trial (PREVENT), a 32 P source wire on a centering catheter was used in three doses of 16 Gy, 20 Gy and 24 Gy compared with control in a heterogenous group of 105 patients with ISR (25), post-PTCA restenosis (7) or de novo lesions (73) treated with either stenting (61%) or PTCA (39%). In this diverse patient group, restenosis rates were reduced (8% vs. 39%, p ϭ 0.012) with similar effects across the radiation doses (84) . A 32 P-␤-emitting stent implanted for 91% to 93% de novo lesions at a number of doses reduces intrastent ISR at six months but is associated with high rates of stent-edge restenosis-the so-called "candy wrapper" effect (85) . Recent data in 22 patients examining the effects at one year demonstrate ongoing intrastent luminal loss, suggesting 32 P-␤-emitting stents may also be simply delaying but not preventing ISR (90) . Problems with radiation therapy. Despite recent Food and Drug Administration approval for two intracoronary radiation delivery devices, there remain a number of concerns (78, 91) . The optimal dosage for either ␥-or ␤-based radiation therapy is not known (92) . Doses given in clinical trials have largely been based on pig studies of stenting or angioplasty alone, which have suggested that a mean dose of 12 Gy to 18 Gy at a depth of 2 mm is optimal (77). This issue is important, since these studies in pigs have suggested that a dose of Ͻ10 Gy may even be stimulatory (93) , and prior clinical experience indicates that doses Ͼ50 Gy for Hodgkin's disease may be associated with late coronary aneurysm formation or further coronary disease (94) . Practical considerations such as local anatomy and difficulty centering delivery devices often mean dosing is variable along the course of a vessel (77, 92, 95) -concerns recently born out by clinical trial evidence showing that ␥-radiation may be less effective in treating long lesions (96) . Similar practical considerations include "geographic miss," a term adopted from radio-oncology to describe the development of a new stenosis at the edge of an irradiated area. This is reported to be due to the combination of injury and low-dose radiation and includes the "candy wrapper" effect observed in relation to 32 P-␤-emitting stents (97, 98) . Another alternative method of delivery is a liquid 188 Refilled balloon, which avoids centering difficulties but carries its own risks (99) . Late stent thrombosis has also been reported in a number of radiation trials, of concern because of the frequency (6% to 7%) and the timing (Ͼ3 months) (77) . The Beta-Cath trial documented a stent thrombosis rate of 6.6% (100); the ␥-WRIST trial reported rates of 7% (82) . Neither trial gave prolonged antiplatelet therapy, and subsequent approaches of six months and one year antiplatelet treatment may reduce rates of stent thrombosis (101, 102) , although it is notable that in the WRIST PLUS trial a relatively high rate of 2.5% late stent thrombosis was still observed with a six month course of clopidogrel and aspirin (103) . There is some evidence that this risk is reduced if further stenting is not performed after irradiation (100, 104) . Other findings within six months of coronary radiation therapy include coronary aneurysms (105, 106) and acellular, necrotic areas of tissue-so-called "black holes." These "black holes" are significant, at least in part, because they contain proteoglycan and other prothrombotic material (Serruys PW, unpublished data, 2001 ) (107) . Thus, coronary radiation for ISR appears to show promising early benefit. The long-term benefits and associated risks, however, remain unclear (78) .
STRATEGIES FOR PREVENTION OF ISR
Stents. There has been great interest in the nature of stents themselves and the means used to implant them as stimuli for ISR (108, 109) . Stent design, composition, length, as well as stent guidance strategies, such as intravascular ultrasound and measures of coronary flow have received considerable attention and are fully discussed elsewhere (51, 110) . More recently, there has been great interest in the possibility that stents may be coated with slowly eluting antirestenotic agents (111) . Polymer-coated stents initially provoked excessive reactions (112), but subsequent coatings using phosphorylcholine-based polymers have not had this effect and may prove a useful drug delivery platform (113) . A number of diverse agents have been shown to elute slowly from polymer coatings and are associated with reduced NI formation in animal models (Table 2A) . Two agents in particular have undergone pilot studies in humans (114, 115) . The first, sirolimus, is a naturally occurring compound derived from the streptomyces fungus and stimulates p27 kip1 levels causing cyclin-Cdk complex inhibition and cell cycle arrest (116) . In two groups of 15 patients treated with a sirolimus-coated stent (140 g/cm 2 ), either as a fast (15 day) or slow (Ͼ28 day) release formulation, negligible NI regrowth was observed at four months (114) . The recently reported Rapamycin-Eluting Versus Plain Polymer Stents (RAVEL) trial randomized 238 patients to a sirolimus-coated stent or conventional stent for de novo coronary lesions and found a zero restenosis rate in the sirolimus group (vs. 26%, p Ͻ 0.0001), clearly a finding of huge implications. Similarly, paclitaxel, a naturally occurring compound from the Pacific yew tree with potent antiproliferative effects, thought to be due to an alteration in microtubular function, has shown promising early results in 14 patients stented with a paclitaxel derivative impregnated sleeve incorporated into a stent design (117) . Both agents have now proceeded to clinical trials (Table 2B) (115, 117, 118) . Clearly there remain questions as to the most suitable agent, toxicity and how multiple or overlapping drug-eluting stents can be used safely (119) . There has also been the observation that stent-based drug delivery results in marked spatial variations in delivered drug dose (120) and reports of late stent thrombosis associated the paclitaxel stents, although it is unclear whether this is due to the drug or the polymer sleeve (121).
Conventional drugs.
A large number of conventional, systemically delivered drugs have reduced NI formation in a variety of animal models, but, with the exceptions of probucol, these have not translated to reduced restenosis after PTCA in the human (37, 122, 123) . However, as previously discussed, ISR is comprised principally of NI formation, whereas restenosis after PTCA is multifactorial (12) . Therefore, drugs inhibiting SMC proliferation and migration might be useful more specifically in reducing rates of ISR. One such agent is troglitazone, which appeared to reduce NI formation in a small series of 52 patients (124). Another agent is tranilast, which has multiple effects, including inhibition of SMC proliferation and migration (125) , reduces ISR in the porcine coronary model (126) but appears to show no benefit in recently completed large Phase III Prevention of Restenosis with Tranilast and its Outcomes (PRESTO) trial (127) . Nucleic acid-based drugs. Nucleic acid-based drugs provide novel therapeutic options for the treatment of restenosis as well as other conditions (128) . The broad principal behind nucleic acid-based drugs is to specifically target and inhibit a regulatory gene that plays an important role in a pathogenic process, classically by creating a molecule of ribonucleic acid (RNA) or DNA that undergoes complementary base pairing with its endogenous target (129).
Nucleic-acid based drugs can broadly be divided into three main types: antisense (AS), ribozymes (RZs) and DNAzymes (DZs). Antisense molecules are single-stranded DNA molecules that form an RNA-DNA duplex with target messenger RNA (130) . Antisense oligodeoxynucleotides targeting the proto-oncogenes c-myb and c-myc inhibit NI formation in rat and pig models of injury (131) (132) (133) , including stenting (134) . However, to date, the only reported use of AS to prevent ISR in humans using a locally delivered AS molecule targeting c-myc showed no benefit (135) . Ribozymes are RNA-based molecules with the advantage of the ability to cleave their target messenger RNA in an enzymatic fashion (136, 137) . An RZ targeting c-myb inhibits SMC proliferation and NI formation after balloon injury to the rat carotid artery (138) . Similarly, RZs targeting transforming growth factor-␤ 1 also inhibit NI formation in the rat model (139) . A chimeric DNA/RNA hammerhead RZ targeting proliferating cell nuclear antigen reduces NI formation by 28% in the pig coronary stent model (140) .
A further refinement to nucleic acid gene targeting strategies has been the development of DZs. These are single-stranded DNA molecules with catalytic domains capable of RNA cleavage at high efficiencies, with added stability conferred by their DNA structure and base modifications (141, 142) . Locally delivered DZs targeting the zinc finger transcription factor Egr-1 inhibit NI formation in the rat carotid injury model by more than 50%, the first such demonstration of the use of DZs in vivo (143) . More recently, DZs targeting the human version of Egr-1 have been shown to inhibit ISR in the porcine coronary stent model (144) . Recently, the expression profile of a large number of known genes was identified in human in-stent restenotic tissue at the time of revascularization (145) . One gene upregulated was FK506 binding protein 12, the receptor for sirolimus, an intriguing finding given the low rates of ISR recently reported using sirolimus-coated stents (114, 146) . A number of other genes were also identified, raising the possibility that key mediators of NI formation upregulated in ISR could systematically be targeted with gene-specific strategies such as nucleic acid-based methodologies. Gene transfer. Gene transfer is defined as the direct introduction of a desirable gene into a local environment, with the aim of increasing the function of that gene to gain pathophysiologic benefit (147) . As such, gene transfer has been viewed as having the potential to be more specifically targeted and more suited to local therapy than conventional drug treatment. The first description of direct gene transfer into the vasculature was over a decade ago (148) and has since been described in a number of cardiovascular contexts including atherosclerosis, angiogenesis and ischemia (149 -151) . Restenosis or ISR, in many ways, has been seen as an ideal pathogenic process to be treated by gene transfer in that the onset of the restenotic process is largely known and the site of restenosis is localized and readily accessible (152, 153) .
A large number of gene products have been investigated as potential targets for gene transfer and tested in both animals and in preliminary studies in humans (Table 3) . These genes have been selected to attempt modification of a number of processes focusing on SMC proliferation but including cell migration, thrombosis and endothelial function (151, 153) . Studies have shown a generally consistent effect in the order of 30% to 70% inhibition of NI formation and, significantly, a number of these approaches have entered phase I human trials. Early reports suggest this approach is well tolerated (154) .
Most studies have used adenovirus vectors to achieve gene transfection, although plasmid DNA, either naked or with a carrier (usually lipid) molecule, has also been employed (153) . Other alternatives are retroviruses and adenoassociated viruses (153) . Adenoviruses have the advantage as vectors in that they can produce large amounts of highly purifed recombinant virus (155) . However, there have been recent concerns that adenoviruses may induce inflammation, particularly when introduced via the intraluminal route (156, 157) and may promote thrombus formation (158) . These concerns have not yet been reported using naked plasmid DNA. As to the question of how to achieve local delivery, catheter-based delivery devices for vascular gene transfer have been investigated for restenosis, all with important limitations (159 -161) . More recently, a high transfection efficiency has been achieved with a DNA- *These studies showed diminished effects at later timepoints; †neointima:media ratio inhibition. Details of individual studies are available from the authors. AV ϭ adenovirus; HVJ/L ϭ haemaggluting virus of Japan/liposome; MMP ϭ matrix metalloproteinase; NI ϭ neointima; PDGF ␤ R ϭ Platelet-derived growth factor ␤ receptor; P/L ϭ plasmid/lipid; PG ϭ prostaglandin; RV ϭ retrovirus; TIMP ϭ tissue inhibitor of metalloproteinase; VEGF ϭ vascular endothelial growth factor.
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Coronary In-Stent Restenosis eluting polylactic-polyglycolic acid-coated stent in porcine arteries (53) , suggesting that local gene transfer may be possible using a coated stent. While studies of gene transfer for restenosis are still at an early stage, the results of preliminary human trials are promising. Moreover, the potential advantages of using local gene delivery to treat a local iatrogenic process are significant and likely to see continued research effort (152) . Other treatments. There is the recent suggestion that novel physical therapies may be useful in the treatment of ISR: two examples being high-frequency ultrasound and low-power red laser light (162, 163) . Ultrasound can inhibit vascular SMC migration and proliferation, and intravascular ultrasound at 700 kHz delivered to porcine coronary arteries for 5 min after stenting reduces cell proliferation at seven days, and NI thickness at 28 days (162). Low-power red laser light enhances endothelial cell growth in vitro and in vivo, and preliminary studies suggest that it is associated with low rates of ISR (163) .
CONCLUSIONS
In-stent restenosis is an emerging pathobiologic process, histologically comprised largely of NI formation with, until recently, limited treatment options available for both treatment and prevention. Recent advances in gene modification and gene transfer therapies and, more particularly, in local stent-based drug delivery systems make it conceivable that the incidence of ISR-currently the Achilles' heel of interventional cardiology-will now be seriously challenged. 
